Literature DB >> 2491934

Simultaneous infusion of nitroglycerin and nitroprusside to offset adverse effects of vasopressin during portosystemic shunting.

K R Sirinek1, D K Adcock, B A Levine.   

Abstract

In the present study, 52 patients with cirrhosis, portal hypertension, and variceal hemorrhage underwent either an elective or an emergency side-to-side portacaval shunt operation. Vasopressin was infused intravenously at 60 units/hour from just prior to abdominal incision until completion of the anastomosis. Eight of 35 patients who received vasopressin alone (23 percent) tolerated increased doses of 75 to 90 units/hour to obtain hemostasis. Four of 52 patients required simultaneous infusion of sodium nitroprusside to correct systemic hypertension. An additional 15 percent reduction in portal venous pressure occurred in these patients. Eleven of 13 patients with vasopressin-induced myocardial ischemia responded to simultaneous infusion of nitroglycerin. Further prospective studies are indicated to adequately delineate the dose and duration of therapy with either nitroprusside or nitroglycerin for simultaneous administration with intravenous vasopressin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491934     DOI: 10.1016/0002-9610(89)90416-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

Review 1.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Is there still a place for vasopressors in the treatment of cardiac arrest?

Authors:  Claudio Sandroni; Fabio Cavallaro; Massimo Antonelli
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

3.  Vasopressin decreases neuronal apoptosis during cardiopulmonary resuscitation.

Authors:  Chi Ma; Zhe Zhu; Xu Wang; Gang Zhao; Xiaoliang Liu; Rui Li
Journal:  Neural Regen Res       Date:  2014-03-15       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.